2.11  0.23 (12.23%)		11-28 16:00
Open: 1.9493 High: 2.27 Volume: 76,812		Pre. Close: 1.88 Low: 1.92 Market Cap: 80(M)

Short term
Mid term
Targets	6-month :	2.94	1-year :	3.67
Resists	First :	2.51	Second :	3.15
Pivot price	2.05
Supports	First :	1.5	Second :	1.24
MAs	MA(5) :	1.82	MA(20) :	2.19
	MA(100) :	1.39	MA(250) :	1.19
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	28.9	D(3) :	21.4
RSI	RSI(14): 52.3
52-week	High :	3.15	Low :	0.73

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ESLA ] has closed below upper band by 46.5%. Bollinger Bands are 173.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 41 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.98 - 1.99	1.99 - 2
Low:	1.81 - 1.82	1.82 - 1.83
Close:	1.87 - 1.88	1.88 - 1.89

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Tue, 04 Nov 2025
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mon, 03 Nov 2025
Estrella Immunopharma stock soars after 100% complete response rate in trial - Investing.com

Mon, 03 Nov 2025
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients - Business Wire

Thu, 23 Oct 2025
Biotech Watch: Estrella's ARTEMIS T-Cell Platform Keeps It In Focus - RTTNews

Mon, 06 Oct 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements - Business Wire

Mon, 29 Sep 2025
Estrella Immunopharma regains Nasdaq compliance on bid price and market value - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	37 (M)
Shares Float	11 (M)
Held by Insiders	70.3 (%)
Held by Institutions	2 (%)
Shares Short	63 (K)
Shares Short P.Month	26 (K)

EPS	-0.24
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-8.8
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-30.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.